BackQuest Diagnostics Overview
Quest Diagnostics, Inc.

Quest Diagnostics Target Price

Analysts' average 12-month price target for Quest Diagnostics is $240.

Get informed when a big investor buys or sells

+ Follow

Share Price

$237.77

Average Target Price

$241.001.4% upside

8 analysts in the last 4 months

High: $260 | Low: $225

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-29Argus Research$2609.3% upsideOpen
2026-07-24UBSKevin Caliendo$2322.4% downsideOpen
2026-07-24Robert W. Baird$2557.2% upsideOpen
2026-07-23Barclays$2505.1% upsideOpen
2026-07-23Jefferies$2453% upsideOpen
2026-07-13Robert W. Baird$2360.7% downsideOpen
2026-04-21Evercore ISI$2255.4% downsideOpen
2026-04-21Jefferies$2255.4% downsideOpen
2026-04-08Evercore ISI$21011.7% downsideOpen
2026-02-12Mizuho Securities$2351.2% downsideOpen
2026-02-11UBS$21011.7% downsideOpen
2026-02-11Truist Financial$2207.5% downsideOpen
2026-02-11Evercore ISIElizabeth Anderson$2207.5% downsideOpen
2026-02-11Robert W. Baird$2197.9% downsideOpen
2026-02-10JefferiesTycho Peterson$2207.5% downsideOpen
2026-01-30Barclays$21011.7% downsideOpen
2025-10-27Piper Sandler$20015.9% downsideOpen
2025-10-22Truist Financial$20513.8% downsideOpen
2025-10-22Morgan StanleyErin Wright$20712.9% downsideOpen
2025-10-22Barclays$19518% downsideOpen
2025-10-21Jefferies$2159.6% downsideOpen
2025-10-21Leerink Partners$21011.7% downsideOpen
2025-10-17UBSKevin Caliendo$19020.1% downsideOpen
2025-10-17Mizuho Securities$21011.7% downsideOpen
2025-10-14Truist Financial$19518% downsideOpen
2025-10-08Evercore ISI$19020.1% downsideOpen
2025-10-02Barclays$19020.1% downsideOpen
2025-08-25Robert W. Baird$19418.4% downsideOpen
2025-07-23Evercore ISIElizabeth Anderson$18522.2% downsideOpen
2025-04-02Redburn PartnersJamie Clark$19518% downsideOpen
2025-02-03Piper SandlerDavid Westenberg$18024.3% downsideOpen
2025-01-31Truist FinancialDavid MacDonald$18223.5% downsideOpen
2025-01-31Robert W. BairdEric Coldwell$18920.5% downsideOpen
2024-10-23CitigroupPatrick Donnelly$18522.2% downsideOpen
2024-10-23Leerink PartnersMichael Cherny$16530.6% downsideOpen
2024-10-23BarclaysStephanie Davis$16829.3% downsideOpen
2024-10-23Robert W. BairdEric Coldwell$18223.5% downsideOpen
2024-10-22CFRAPaige Meyer$17825.1% downsideOpen
2024-10-07Truist FinancialDavid MacDonald$16530.6% downsideOpen
2024-07-29Mizuho SecuritiesAnn Hynes$16032.7% downsideOpen
2024-07-24Robert W. BairdEric Coldwell$15435.2% downsideOpen
2024-07-15Truist FinancialDavid MacDonald$15833.5% downsideOpen
2024-04-25BarclaysStephanie Davis$14439.4% downsideOpen
2024-02-07JefferiesBrian Tanquilut$15534.8% downsideOpen
2023-02-03Wells Fargo$14041.1% downsideOpen
2023-01-06Morgan Stanley$15833.5% downsideOpen
2022-11-17Citigroup$12547.4% downsideOpen
2022-05-03Morgan Stanley$14240.3% downsideOpen
2022-04-25Wells Fargo$15036.9% downsideOpen
2022-04-09CitigroupRalph Giacobbe$17526.4% downsideOpen

Quest Diagnostics (DGX) FAQ

Quest Diagnostics (DGX) currently reports a target price of $240. Use the charts on this page to explore Quest Diagnostics's target price history and peer comparisons.

Analysts' average 12-month price target for Quest Diagnostics is $240, about 1.4% upside from the current share price of $237.77. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $240, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Quest Diagnostics, and consider following DGX for alerts when major investors trade the stock.

Quest Diagnostics is classified in the Healthcare sector. On target price, it currently shows $240. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DGX with unrelated industries.